Previous 10 | Next 10 |
2023-12-19 17:11:10 ET DENVER, Colo., Dec. 19, 2023 ( www.247marketnews.com )- 24/7 Market News covered the following companies today; Compugen Ltd (NASDAQ: CGEN), Gilead Sciences, Inc. (NASDAQ: GILD), Infobird Co Ltd (NASDAQ: IFBD), and Panbela Therapeutics Inc (NASDAQ: PBLA). Comp...
2023-12-19 12:24:05 ET DENVER, Colo., Dec. 19, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Compugen Ltd (NASDAQ: CGEN), Infobird Co Ltd (NASDAQ: IFBD), Mama`s Creations Inc (NASDAQ: MAMA), Panb...
2023-12-19 10:56:18 ET More on Compugen, Gilead Sciences, etc. Gilead Sciences Is Building A Diversified Portfolio Gilead Sciences, Inc. (GILD) Presents at Piper Sandler 35th Annual Healthcare Conference (Transcript) Gilead Sciences, Inc. (GILD) Presents at 6th Annua...
2023-12-19 10:25:45 ET An Illinois-based %Biotech company is already off to the races on Tuesday after it was announced that the company has entered into an agreement with %GileadSciences (Nasdaq: GILD) to exclusively license its potential first-in-class, pre-clinical antibody progr...
2023-12-19 07:26:41 ET DENVER, Colo., Dec 19, 2023 ( www.247marketnews.com )- Gilead Sciences, Inc. (NASDAQ: GILD) and Compugen Ltd. (NASDAQ: CGEN) jointly announced, this morning, that they signed an exclusive license agreement for its potential first-in-class, pre-clinical antibody pr...
Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer PR Newswire Dosing of first patient in Phase 3 trial of rilvegostomig, a PD-1/TIGIT bispecific antibody, will...
Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 Biology PR Newswire Conference call today, December 19, 2023 , 8:30 AM ET to discuss the license agreement ...
– Gilead Will Have Exclusive Rights to Later Stage Development and Commercialization of Anti-IL18 Binding Protein Antibodies with Potential to Treat Various Tumor Types – – Gilead to Make $60 Million Upfront Payment and $30 Million in a Near Term Milestone Payment w...
2023-11-07 14:29:07 ET Compugen Ltd. (CGEN) Q3 2023 Earnings Conference Call November 7, 2023 8:30 AM ET Company Participants Yvonne Naughton – Head-Investor Relations and Corporate Communications Anat Cohen-Dayag – President and Chief Executive Officer...
2023-11-07 07:06:52 ET More on Compugen Seeking Alpha’s Quant Rating on Compugen Historical earnings data for Compugen Financial information for Compugen For further details see: Compugen GAAP EPS of -$0.11 misses by $0.02
News, Short Squeeze, Breakout and More Instantly...
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024 PR Newswire HOLON, Israel , July 23, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target ...
Compugen to Present at Upcoming Antibody Industrial Symposium PR Newswire HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, t...
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig PR Newswire Phase 3 trial evaluating rilvegostomig as monotherapy and in combination with AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in ...